Becton Dickinson shares climbed 1.8% in pre-market trading following the company’s fiscal third-quarter 2026 report, which outperformed Wall Street estimates on both earnings and revenue.
Quarterly performance
The company posted adjusted earnings per share of $3.23, surpassing the analyst consensus by $0.10, where estimates had stood at $3.13. Quarterly revenue totaled $5.0 billion versus the expected $4.89 billion, equating to reported growth of 5.4% compared with the same period a year earlier.
Guidance and management commentary
Management raised full-year fiscal 2026 adjusted diluted EPS guidance to a range of $12.62 to $12.72, exceeding the prior consensus level of $12.56. The move signals management’s increased confidence in the trajectory of the company’s ongoing portfolio transformation.
Analyst reaction
On the analyst front, TD Cowen kept its Hold rating on Becton Dickinson but revised its price target upward to $182 from $163. The firm said the beat-and-raise quarter improved its conviction in the company’s earnings path, prompting the price-target increase while leaving the rating unchanged.
Context for investors
Investors received the results in a market that offered mixed signals. The S&P 500 and the Dow Jones moved modestly higher while the Nasdaq dipped slightly, indicating that Becton Dickinson’s pre-market strength was largely driven by company-specific news rather than broad market momentum.
The quarter was viewed as notable because year-over-year comparisons had been complicated by prior spin-off activity, making the company’s organic revenue growth and margin performance particularly important for investors concerned about execution risk. In addition, the healthcare and medical technology sector has been under scrutiny for procedure volumes and the effects of portfolio reshaping, so a clean beat-and-raise quarter carries additional weight for the group.
Market impact
Taken together, the earnings beat, raised full-year profit outlook, and the constructive analyst price-target revision gave investors reasons to buy BDX ahead of the opening bell. That buying pressure pushed the stock toward $173.70, well above the prior session close of $170.66.
Summary
Becton Dickinson’s fiscal Q3 beat on both earnings and revenue, combined with an upgraded full-year adjusted EPS outlook and a higher analyst price target, drove a pre-market uptick in the stock. The results were viewed as reassuring amid prior spin-off-related distortions and sector scrutiny over procedure volumes and portfolio reshaping.